Within the top 10 holdings, small- and mid-cap names held by the fund include relatively well-known names such as Marco Polo ...

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...

Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs. Recludix was named a 2024 Fierce ...

Abivax stock (EPA: ABVX) surged roughly 30% in early Paris trading Monday after French media reported that US pharmaceutical giant Eli Lilly was preparing a €15 billion ($17.5 billion) acquisition ...

In January 2022, Garutadustat, the innovative, potentially best-in-class, oral PHD inhibitor was nominated as a preclinical ...

PRESS RELEASE Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported OutcomesFirst conceptual ...

Immorta Bio Inc., a scientific longevity company dedicated to Treating Diseases of Aging and Treating Aging as Disease(TM), today announced new data demonstrating that its combination therapy of ...

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming ...

Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...

Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for ...

CBSE Class 12 Chemistry is a crucial subject that requires strong conceptual clarity and regular practice to score well in ...